[Skip to Navigation]
Sign In
Comment & Response
October 10, 2019

Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma—In Reply

Author Affiliations
  • 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
JAMA Oncol. 2019;5(12):1806-1807. doi:10.1001/jamaoncol.2019.4058

In Reply We appreciate the letter from Dr Coriat and colleagues in response to our recent report on the combination of hepatic arterial infusion chemotherapy (HAIC) with sorafenib.1 We would like to thank them for their interest in our study. In their letter, they raised 2 issues for discussion: (1) restricting the use of the hepatic arterial infusion strategy to an oxaliplatin-based regimen and to patients with portal vein tumor thrombosis and (2) evaluating HAIC with gemcitabine plus oxaliplatin (GEMOX) with sorafenib.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words